Related Experiment Video
Updated: Jul 11, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Treatment of acute ischemic stroke
1Department of Neurology, Northwestern University Medical School, Chicago, IL 60611, USA.
Treating acute ischemic stroke is challenging. Current therapies like recombinant tissue plasminogen activator have narrow treatment windows and risks, highlighting the urgent need for better stroke prevention strategies.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Emergency Medicine
Background:
- Acute ischemic stroke treatment remains a significant clinical challenge.
- Current therapeutic options have limitations, including narrow time windows and potential complications.
Purpose of the Study:
- To review the current landscape of acute ischemic stroke treatments.
- To identify the limitations of existing therapies and the need for improved preventive measures.
Main Methods:
- Literature review of current treatments for acute ischemic stroke.
- Analysis of the efficacy and drawbacks of thrombolytic therapy, anticoagulants, and neuroprotective agents.
Main Results:
- Recombinant tissue plasminogen activator is the only approved intravenous therapy but has a short time window (3 hours).
- Thrombolytic therapy carries a risk of symptomatic cerebral hemorrhage (3-6%).
- Intra-arterial prourokinase is not FDA-approved; aspirin shows limited benefit in preventing recurrent events; heparin and neuroprotective agents lack proven efficacy.
Conclusions:
- Existing treatments for acute ischemic stroke are limited by efficacy, safety, and administration constraints.
- There is an urgent unmet need for improved preventive strategies for patients at risk of stroke.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Venous Thrombosis III: Interprofessional Care
Transient Ischemic Attack l: Introduction
Hemorrhagic Stroke l: Introduction
